ArticleBioMed research international2026
Single-Cell Sequencing Reveals the Immunosuppressive Trajectory in the Tumor Microenvironment of Human Giant Cell Tumor of Bone.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-Cell Sequencing Reveals the Immunosuppressive Trajectory in the Tumor Microenvironment of Human Giant Cell Tumor of Bone.BioMed research international · 2026Article
- Tumor-associated osteoclasts converge on a matrix-sulfation program across human bone tumors.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Giant cell tumor of bone (GCTB) presents considerable complexity in tumor microenvironment (TME) because of its intricate intercellular heterogeneity and the presence of an immunosuppressive milieu. In order to understand the complex gene expression patterns and cell interactions in GCTB, we carried out a thorough investigation using single-cell RNA sequencing (scRNA-seq). Methods: We examined scRNA-seq data from 7091 cells that were collected after surgical removal of GCTB. Following the initial quality control process, 10 separate groups of cells were distinguished, which consisted of dendritic cells, endothelial cells, macrophage cells, mast cells, monocyte cells, neutrophil cells, tumor cells, osteoclast cells, pericyte cells, and T cells. Additional analysis uncovered distinct categories within tumor-associated macrophages (TAMs), CD8+ T cells, and CD4+ T cells. The differentiation mechanisms of TAMs, CD8+ T cells, and CD4+ T cells were explored using pseudo-time trajectory analysis. The CellPhoneDB study revealed the interactions between various cell types within the TME of GCTB. Results: TAMs have been identified as the main infiltrating cells in GCTB. These TAMs exhibit several subtypes that are characterized by specific marker genes and functional states. The identification of several subgroups within CD8+ T cells that are involved in regulating immunological checkpoints underscores the difficulties encountered when attempting to employ immune checkpoint blockade therapy for GCTB. T cell exhaustion poses a major barrier to the efficacy of antitumor immune responses. Research suggests a strong correlation between TAMs and exhausted T cells (Texs) in the TME. The high number of regulatory T cells (Tregs) highlights the immunosuppressive nature of the immunological environment in GCTB. Significant interactions have been observed between TAMs and tumor cells, highlighting their crucial involvement in immune evasion strategies. Conclusion: This scRNA-seq study provides a general overview of the different cellular compositions and immune interactions within GCTB. The identified subtypes and communication networks provide valuable information about the immunosuppressive environment of GCTB, laying the foundation for prospective therapeutic approaches targeting specific cell types or interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.